Targeting the Thromboinflammatory Response to Mitigate Bowel Injury in Necrotizing Enterocolitis

靶向血栓炎症反应以减轻坏死性小肠结肠炎的肠道损伤

• 批准号: 10840235
• 负责人: Thomas G Diacovo
• 金额: $ 23.93万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-07 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10840235
• 关键词: ADAMTS; ADP Receptors; Adhesions; Adult; Affect; Agonist; Animal Model; Binding; Biological; Biological Products; Biophysical Process; Blood Banks; Blood Platelets; Blood Vessels; Cell Proliferation; Cells; Cessation of life; Clinical; Coagulation Process; Collaborations; Collagen; Critical Illness; DNA Damage; Data; Development; Disease; Disease Progression; Event; FDA approved; Future; Genetic; Genetically Modified Animals; Genomics; Goals; Growth; Harvest; Hemorrhage; Hemostatic Agents; Hemostatic function; Human; Immune; Immune system; Immunocompetent; Immunology; Infant; Injury; Integrins; Intestines; Invaded; Ischemia; Knowledge; Life; Mediating; Messenger RNA; MicroRNAs; Modeling; Molecular; Morbidity - disease rate; Mus; Nature; Necrosis; Necrotizing Enterocolitis; Neonatal; Neonatal Intensive Care Units; Neurologic Deficit; Newborn Animals; Newborn Infant; Operative Surgical Procedures; PAWR gene; Pathogenesis; Pathology; Pathway interactions; Peptide Hydrolases; Perforation; Pharmacologic Substance; Plasma; Platelet Transfusion; Play; Population; Positioning Attribute; Preclinical Testing; Premature Infant; Process; Proteins; Public Health; Research; Risk; Role; Secondary to; Severities; Severity of illness; Signal Pathway; Signal Transduction Pathway; Site; Small Intestines; Survivors; System; Testing; Thrombin; Thrombocytopenia; Thrombosis; Thrombus; Transcript; Transfusion; Umbilical Cord Blood; Vulnerable Populations; angiogenesis; biophysical properties; blood product; clinically relevant; combat; design; improved outcome; intestinal barrier; intestinal injury; mitochondrial metabolism; mortality; nanobodies; neonatal mice; neonatal patient; neonate; new therapeutic target; novel; novel therapeutic intervention; pharmacologic; prevent; response; small molecule; targeted agent; thrombogenesis; thromboinflammation; tissue injury; transcriptome; transfusion medicine; von Willebrand Factor

Necrotizing enterocolitis (NEC) is a devastating disease affecting premature infants that can result in extensive bowel necrosis and perforation. The most severe forms are associated with high morbidity and mortality with survivors at risk for significant neurological deficits. Sadly, little progress has been made towards improving outcomes, which is due in part to its multifactorial pathogenesis that includes immaturity of the intestinal barrier, ischemic tissue injury, and hyperinflammation secondary to immaturity of the immune system. In addition, there is evidence suggesting that platelets (both endogenous and transfused) contribute to NEC pathology. The goal of the proposed research is to test the hypothesis that the platelet-Von Willebrand Factor (VWF) axis and its role in thromboinflammation contributes to the development / progression of NEC. In support of this premise are preliminary results demonstrating that: (i) absence of VWF protects neonatal mice from developing NEC; (ii) genetic deletion of ADAMTS13, a protease that cleaves VWF thereby limiting thrombus size, augments disease severity; and (iii) administration of blood bank stored human platelets to genetically modified neonatal mice that support human but not mouse platelet mediated thrombosis results in increased tissue injury, enhanced bacterial invasion, alteration in local immunocompetent cell populations, and even death when subjected to NEC- inducing conditions. However, the specific molecular mechanisms that contribute to these observations and whether other platelet adhesion and signaling pathways are involved in this process are largely unknown. Based on our vast knowledge of the platelet-VWF axis in supporting hemostasis and thrombosis, we will now determine its role in the development and progression of NEC. This will involve the use of genetically modified animals, novel intravital models, assessment of intestinal immune cell populations by FACs and single cell genomic analyses, unique biologics and small molecules that will further inform on pathways and potential therapies. Hypotheses will be tested in three aims: In Aim 1, we will further delineate the role of VWF in NEC, with focus on the platelet binding region (A1 domain), as well as key platelet adhesion and signaling pathways by using genetically modified animal models. Based on these results, Aim 2 will evaluate novel pharmacologic agents that target the platelet-VWF axis in neonatal mice undergoing NEC induction. In Aim 3, we will test the hypothesis that blood bank stored human platelets can contribute to transfusion-induced bowel injury and that the hypothrombogenic nature of those derived from cord blood may be protective. The proposed studies will make a significant conceptual advancement in knowledge by defining how the platelet- VWF axis and its role in thrombo-inflammation contributes to tissue injury in NEC. It will also lead to the development of novel or identification of FDA approved pharmaceuticals that can be repurposed to reduce the morbidity and mortality associated with this devastating disease.

坏死性小肠结肠炎 (NEC) 是一种影响早产儿的破坏性疾病，可导致广泛的死亡 肠管坏死和穿孔。最严重的形式与高发病率和死亡率相关 幸存者面临严重神经缺陷的风险。遗憾的是，在改进方面进展甚微 结果，部分原因是其多因素发病机制，包括肠道屏障的不成熟， 缺血性组织损伤和免疫系统不成熟继发的过度炎症。此外，还有 有证据表明血小板（内源性和输注性）会导致 NEC 病理学。 本研究的目的是检验血小板-血管性血友病因子 (VWF) 轴的假设 其在血栓炎症中的作用有助于 NEC 的发生/进展。为了支持这一点 前提是初步结果表明：(i) 缺乏 VWF 可保护新生小鼠免于发育 国家电气公司； (ii) ADAMTS13（一种裂解 VWF 从而限制血栓大小的蛋白酶）的基因缺失会增加 疾病严重程度； (iii) 将血库储存的人类血小板用于转基因新生儿 支持人类而非小鼠血小板介导的血栓形成的小鼠会导致组织损伤增加，增强 细菌入侵、局部免疫活性细胞群的改变，甚至在受到 NEC- 影响时死亡 诱发条件。然而，促成这些观察和结果的具体分子机制 其他血小板粘附和信号传导途径是否参与该过程尚不清楚。 基于我们对血小板-VWF 轴在支持止血和血栓形成方面的丰富知识，我们现在将 确定其在 NEC 的发展和进展中的作用。这将涉及使用转基因技术 动物、新型活体模型、通过 FAC 和单细胞评估肠道免疫细胞群 基因组分析、独特的生物制剂和小分子将进一步了解途径和潜力 疗法。假设将在三个目标中进行检验：在目标 1 中，我们将进一步描述 VWF 在 NEC 中的作用， 重点关注血小板结合区域（A1 结构域）以及关键的血小板粘附和信号通路 通过使用转基因动物模型。根据这些结果，目标 2 将评估新的药理学 在接受 NEC 诱导的新生小鼠中靶向血小板-VWF 轴的药物。在目标 3 中，我们将测试 血库储存的人类血小板可能导致输血引起的肠损伤的假设 源自脐带血的物质的低血栓形成特性可能具有保护作用。 拟议的研究将通过定义血小板如何在知识上取得重大的概念进步。 VWF 轴及其在血栓炎症中的作用导致 NEC 中的组织损伤。这也将导致 开发新的药物或鉴定 FDA 批准的药物，这些药物可以重新利用以减少 与这种毁灭性疾病相关的发病率和死亡率。